Ten stocks capped off Friday’s trading boasting strong gains, defying a market bloodbath, as investors took path from a flurry of strong corporate earnings and upbeat outlooks, among others. Of the 10 in the list, six hit new record highs.
In contrast, Wall Street’s main indices all finished in the red, led by the Nasdaq, down 1.59 percent, followed by the S&P 500 losing 1.33 percent, and the Dow Jones, dropping 0.95 percent.
In this article, we spotlight the 10 top-performing companies on Friday and break down the reasons behind their gains.
To come up with the list, we focused on the companies with a $2 billion market capitalization and 5 million shares in trading volume.
Photo by Tima Miroshnichenko on Pexels
10. Petroleo Brasileiro SA (NYSE:PBR)
Petroleo Brasileiro soared to a new two-year high on Friday after three straight days of decline, as investor sentiment was buoyed by its return to profitability and the distribution of $1.5 billion in dividends.
At intra-day trading, Petroleo Brasileiro SA (NYSE:PBR) climbed to its highest price of $17.83 before paring gains to finish the session just up by 5.29 percent at $17.62 apiece.
In the fourth quarter last year, Petroleo Brasileiro SA swung to a net income attributable to shareholders of $2.889 billion from a $2.78 billion net loss in the same period a year earlier. Sales revenues jumped by 13 percent to $23.6 billion from $20.8 billion year-on-year.
Petroleo Brasileiro SA attributed the increase to its excellent operational results, backed by an 11 percent jump in total oil and gas production, which offset a 14 percent decline in Brent crude prices.
Following the results, investment firm Morgan Stanley raised its price target to $20 from $17.50 previously and maintained an “overweight” rating for the stock, amid management signals that it would readjust prices regardless of international benchmarks while avoiding immediate volatility pass-through to domestic prices.
“We expect upward earnings revisions and remain OW (overweight),” it said.
9. Equinor ASA (NYSE:EQNR)
Equinor rallied for a third consecutive day on Friday to hit a new two-year high, mirroring the industry’s rally backed by the continued surging crude oil prices.
At intra-day trading, Equinor ASA (NYSE:EQNR) jumped to its highest price of $33.64 before paring a few cents to finish the session just up by 5.76 percent at $33.59 apiece.
As of writing, WTI increased by 12.21 percent to $90.90 per barrel, while Brent crude was up by 8.86 percent at $92.98 per barrel amid the intensified war in the Middle East.
Last month, Equinor ASA announced a net income of $5.06 billion in full-year 2025, marking a 43 percent decline from the $8.8 billion in 2024. Total revenues and other income, on the other hand, inched up by 3 percent to $106.46 billion from $103.77 billion year-on-year.
For the fourth quarter alone, net income stood at $1.3 billion, lower than the $2 billion in the same period a year earlier. Total revenues declined by 8 percent to $25.3 billion from $27.65 billion year-on-year.
“With new fields on stream and strong operations, we deliver record-high production and competitive returns in 2025. We continue to allocate capital to further develop and maximise value from the Norwegian continental shelf. At the same time, we are delivering focused growth in our international oil and gas portfolio and building our integrated power business, now focusing on the execution of already-sanctioned projects,” he added.
For this year, Equinor ASA is targeting to ramp up production by 3 percent year-on-year. It also announced a $1.5 billion share buyback program to boost shareholder value.
8. XPeng Inc. (NYSE:XPEV)
XPeng rallied for a third consecutive day on Friday, as investors positioned portfolios ahead of the release of its earnings performance in the fourth quarter and full-year 2025.
According to the company, it is scheduled to release its financial and operating highlights for the said periods before market open on Friday, March 20. An earnings call will be held to discuss the results.
For the fourth quarter alone, XPeng Inc. (NYSE:XPEV) is targeting to report a 33.5 percent to 42.8 percent jump in total revenues to a range of 21.5 billion yuan to 23 billion yuan.
However, the company fell short of its vehicle delivery targets of 125,000 to 132,000 units, having turned over only 116,249 smart vehicles in the fourth quarter, based on its monthly reports for October, November, and December.
In the first two months of the year alone, XPeng Inc. delivered a total of 35,267 units, of which 20,011 units were turned over in January, while 15,256 vehicles were distributed last month.
XPeng Inc. is a smart electric vehicle company based in China targeting the technology-savvy middle-class markets.
7. JD.com Inc. (NASDAQ:JD)
JD rallied for a second day on Friday, jumping 6.12 percent to close at $27.03 apiece, after an investment firm reaffirmed its “buy” recommendation and price target for the stock.
In its market report, Benchmark maintained its rating and $38 price target for JD.com Inc. (NASDAQ:JD) following the results of its earnings performance last year, saying that the latter showed resiliency in the fourth quarter despite trade-in subsidy tapering and category headwinds.
In the full-year period, JD.com Inc. said that it dropped its net income attributable to shareholders by 50 percent to $2.8 billion from $5.67 billion in 2024. However, total net revenues increased by 18 percent to $187.2 billion from $158.76 billion year-on-year.
In the fourth quarter alone, JD.com Inc. swung to a net loss attributable to shareholders of $388 million from a $1.35 billion attributable net income in the same quarter a year earlier.
Total net revenues increased by 6 percent to $50.38 billion from $47.5 billion.
To support shareholder value, the company announced the distribution of dividends amounting to $0.5 per ordinary share and $1 per ADS to all holders on record as of April 9, 2026 (Beijing, Hong Kong, and New York time), payable on April 23 for ordinary shareholders, and on April 29 for ADS holders.
6. Lionsgate Studios Corp. (NYSE:LION)
Lionsgate Studios soared to a nearly two-year high on Friday, as investors took heart from its recently clinched partnership with Scentbird for the launch of a new fragrance inspired by one of its highest-grossing films globally.
At intra-day trading, Lionsgate Studios Corp. (NYSE:LION) climbed to its highest price of $11.02 before paring gains to finish the session just up by 6.71 percent at $10.66 apiece.
In a statement, Lionsgate Studios Corp. and Scentbird said that they would offer on the Scentbird platform a Twilight Saga-inspired floral amber fragrance, with notes of decadent macadamia and creamy woods, to capture its fans and evoke its signature atmosphere.
“This collaboration with Scentbird brings The Twilight Saga to life in an immersive and experiential way, captivating fans and first-time discoverers through a scent experience designed to be both shared and collected,” said Lionsgate Studios Corp. Consumer Products Director Debbie Olshan.
The Twilight Eau de Parfum will be available for a limited time through Scentbird via subscription and select à la carte formats.
The Twilight Saga is a five-series film series that has grossed more than $3.36 billion worldwide.
It is the listed firm’s second-highest-grossing film, next to The Hunger Games: Catching Fire.
5. Amprius Technologies Inc. (NYSE:AMPX)
Amprius rallied for a fifth straight day on Friday to hit a new all-time high, as investor optimism was further bolstered by two analysts’ price target upgrades and bullish ratings for its stock.
At intra-day trading, the stock soared to its highest price of $17.29 before paring gains to finish the day just up by 9.67 percent at $16.33 apiece.
In separate market reports, Cantor Fitzgerald and Craig-Hallum raised their price targets for Amprius Technologies Inc. to $20 and $21, from $16 and $17, respectively.
Cantor issued an “overweight” rating while Craig-Hallum assigned a “buy” recommendation, following Amprius Technologies Inc.’s highly optimistic outlook this year, with revenues targeted to grow by 71 percent.
In its latest earnings call, Amprius Technologies Inc. said that it is targeting to further grow its revenues to $125 million this year from $73 million last year. If realized, the company would end the year with a 417-percent revenue jump in just two years, versus only $24.17 million in 2024.
However, it expects to remain at a net loss of $8 million in 2026, but would imply an 82-percent recovery from $44 million in net losses last year.
“2025 marked a year of meaningful commercial progress, as we expanded our customer base to over 550, increased revenue by over 3x, and advanced the adoption of our silicon anode batteries across multiple end markets,” Amprius Technologies Inc. CEO Tom Stepien said.
“Growing demand from existing customers, new program wins, and improved execution across our manufacturing partners drove strong momentum throughout the year. Looking ahead to 2026, we plan to leverage our enhanced supply chain to scale production and meet accelerating market demand, supporting continued accretive growth,” he added.
4. Iovance Biotherapeutics Inc. (NASDAQ:IOVA)
Iovance climbed to a new 52-week high on Friday, extending a three-day run, as investors gobbled up shares after an investment firm doubled its price target for its stock.
At intra-day trading, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) climbed to its highest price of $5.34 before paring gains to finish the session just up by 12.01 percent at $5.13 apiece.
In a market report, UBS raised its price target for the biopharmaceutical company to $4 from $2 previously, albeit remaining “neutral” for the stock.
On the other hand, Iovance Biotherapeutics Inc. maintained a more bullish rating from Wells Fargo, with the investment firm reaffirming its $14 price target and “buy” recommendation.
On Wednesday, March 11, investors will be closely watching out for business updates from Iovance Biotherapeutics Inc. amid its participation in Barclays’ 28th Annual Global Healthcare Conference.
In recent news, the biopharmaceutical firm reported a 5 percent wider net loss last year at $390.98 million versus $372 million in 2024. Total revenues jumped by 60.6 percent to $263.5 million from $164.07 million year-on-year.
In the fourth quarter alone, net loss narrowed by 8 percent to $71.9 million from the $78.5 million in the same period a year earlier, while revenues increased by 17.6 percent to $86.7 million from $73.69 million year-on-year.
3. Marvell Technology Inc. (NASDAQ:MRVL)
Marvell Technology soared by 18.35 percent on Friday to close at $89.57 apiece, as investors took heart from its strong earnings performance for the full fiscal year 2026, swinging to billions of profits from hundred millions of net losses a year earlier.
In an updated report, Marvell Technology Inc. (NASDAQ:MRVL) said that it incurred a $2.67 billion net income in the full fiscal year ending January 31, reversing an $885 million net loss in fiscal 2025.
Net revenues jumped by 42 percent to $8.2 billion from $5.77 billion year-on-year.
In the fourth quarter alone, net income stood at $396.1 million, nearly double the $200.2 million in the same period a year earlier. Net revenues increased by 22 percent to $2.2 billion from $1.8 billion year-on-year.
Marvell Technology Inc. Chairman and CEO Matt Murphy attributed the company’s strong performance from the robust AI demand.
Looking ahead, the company is targeting net revenues for the first quarter of fiscal year 2027 at a midpoint of $2.4 billion, or a 27 percent jump from the $1.895 billion reported in the same period a year earlier.
GAAP diluted earnings per share are targeted at $0.31, plus or minus $0.05, versus $0.20 year-on-year.
2. Samsara Inc. (NYSE:IOT)
Samsara soared by 19.54 percent on Friday to finish at $35.36 apiece, as investor sentiment was bolstered by a stellar earnings performance, having nearly wiped out its losses in the last fiscal year.
In an updated report, Samsara Inc. (NYSE:IOT) said that it narrowed its net losses by 94 percent to $9 million in the fiscal year ending January 31, from a $155 million net loss a year earlier.
Revenues also jumped by 28 percent to $1.6 billion from $1.25 billion year-on-year.
In the fourth quarter alone, Samsara Inc. swung to a net income of $22 million, reversing a net loss of $11.2 million in the same quarter a year earlier. Revenues increased by 28 percent to $444.3 million from $346 million year-on-year.
“Fiscal year 2026 was an outstanding year of durable and efficient growth,” Samsara Inc. CEO Sanjit Biswas said, adding that the performance was driven by the scale of its data asset, which now captures more than 25 trillion data points annually to fuel its AI-powered platform.
For the first quarter of fiscal year 2027, the company is targeting to generate revenues of $454 million to $456 million, or an implied growth of 24 percent year-on-year.
For the full fiscal 2027 alone, revenues are expected to grow between 21 and 22 percent to a range of $1.965 billion to $1.975 billion year-on-year.
1. Day One Biopharmaceuticals Inc. (NASDAQ:DAWN)
Day One soared to a new three-year high on Friday, as investors gobbled up shares following news that it is set to merge with France-based Servier for $2.5 billion.
In a joint statement, Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) and Servier said that they have entered into a definitive agreement under which the latter would acquire the former’s shares at a price of $21.50 apiece. The figure marked a 68 percent upside from its latest closing price.
Following the news, shares of Day One Biopharmaceuticals Inc. at intra-day trade soared to its highest price of $21.23 before paring a few cents to finish the session just up by 65.88 percent at $21.20 apiece.
According to the companies, they expect to close the transaction in the second quarter of the year, subject to customary closing conditions
“Servier’s successful track record in rare cancers and its commitment to advancing targeted therapies make it the ideal home for our portfolio as part of Day One’s mission to bring medicines to patients of all ages with life-threatening diseases,” Day One Biopharmaceuticals Inc. CEO Jeremy Bender said.
“Joining Servier represents a unique opportunity to extend the reach of our science and our lead program in pediatric low‑grade glioma. Importantly, Servier’s dedication to the rare disease community preserves the patient‑first mindset that has defined our company since the beginning and has driven our deep commitment to the communities we serve,” he noted.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.
Hedge Fund Resource Center